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SUMMARY
The discovery, development and optimal utilization of pharmaceuticals can be greatly enhanced by knowledge of their
modes of action. However, many drugs currently on the market act by unknown mechanisms. Untargeted metabolomics
oﬀers the potential to discover modes of action for drugs that perturb cellular metabolism. Development of high resolution
LC-MS methods and improved data analysis software now allows rapid detection of drug-induced changes to cellular
metabolism in an untargeted manner. Several studies have demonstrated the ability of untargeted metabolomics to provide
unbiased target discovery for antimicrobial drugs, in particular for antiprotozoal agents. Furthermore, the utilization of
targeted metabolomics techniques has enabled validation of existing hypotheses regarding antiprotozoal drug mechanisms.
Metabolomics approaches are likely to assist with optimization of new drug candidates by identiﬁcation of drug targets, and
by allowing detailed characterization of modes of action and resistance of existing and novel antiprotozoal drugs.
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INTRODUCTION
Protozoan parasites, including Plasmodium spp.,
Trypanosoma spp. and Leishmania spp., are respon-
sible for diseases that cause signiﬁcant morbidity,
mortality and economic burden, predominantly in
developing countries. There are currently no eﬀective
vaccines available for the prevention of these tropical
diseases, including malaria, human African trypano-
somiasis (HAT), Chagas disease and leishmaniasis,
and therapy relies heavily on antiprotozoal drugs
(Pink et al. 2005; Anthony et al. 2012; Barrett and
Croft, 2012). New antiprotozoals are urgently re-
quired, as most existing drugs suﬀer from one or
more liabilities related to poor eﬃcacy, drug resist-
ance, toxicity, high cost or unsuitable pharmaco-
kinetic properties (Wells et al. 2009; Phillips, 2012).
The lack of suitable treatments for these tropical
diseases is partly due to there having been inadequate
pharmaceutical research eﬀorts during the last cen-
tury (Renslo andMcKerrow, 2006;Wells et al. 2009).
The majority of current antiprotozoal drugs did not
arise from programmes common in contemporary
pharmaceutical development, and the rigorous pre-
clinical and clinical evaluation that is now expected
of new drugs did not accompany registrations of most
of the antiprotozoals (Renslo and McKerrow, 2006).
Indeed, many commonly used antiprotozoal drugs
act by unknown mechanisms, which severely im-
pedes optimal clinical utilization and monitoring for
eﬃcacy, toxicity and resistance.
Fortunately, the pipeline for new antiprotozoal
drugs now looks promising as a result of recent eﬀorts
to screen large compound libraries against these
pathogenic parasites. Hundreds of ‘hit’ compounds
have been identiﬁed that inhibit the in vitro prolifer-
ation of speciﬁc protozoan parasites (Gamo et al.
2010; Guiguemde et al. 2010; Duﬀy andAvery, 2012;
Sykes et al. 2012). It is clear that screening compound
libraries against organisms is superior to primary
screens against individual targets, possibly due to the
fact that key pharmacological criteria such as mem-
brane-permeability are already built into compounds
passing the former type of screen. Amajor bottleneck
in the hit-to-lead optimization pipeline following
identiﬁcation of hits in whole organism screens
relates to the lack of mechanistic information con-
cerning their modes of action (Guiguemde et al.
2012). Identiﬁcation of target(s) for hit compounds
allows rational medicinal chemistry to improve
selectivity of binding to the parasite target, and
ensures that structural modiﬁcations to enhance the
pharmacokinetic and toxicity proﬁles are not likely
to compromise activity. The availability of methods
to identify modes of action for antiprotozoal com-
pounds in an untargeted manner would greatly
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enhance the eﬃciency of drug discovery for parasitic
diseases.
Metabolomics is an emerging technology that pro-
vides an untargeted overview of cellular metabolism
by the simultaneous detection and relative quan-
tiﬁcation of hundreds of small molecules (<1500Da)
in a biological system (Scalbert et al. 2009; Scheltema
et al. 2010; Creek et al. 2012a; Dunn et al. 2012).
Metabolomic proﬁling of protozoan parasites treated
with antiprotozoal compounds can detect drug-
induced changes to parasite metabolism and identify
the individual metabolites and pathways that are
directly perturbed. This provides a rapid and un-
biased method to discover likely drug targets
(Beyoğlu and Idle, 2013).
The untargeted nature of metabolomics has
allowed rapid and unbiased classiﬁcation of numer-
ous antimicrobial compounds according to their
modes of action (Gao et al. 2007; Liu et al. 2009;
Halouska et al. 2012). Investigation of the metabolic
response of Staphylococcus aureus to triphenylbis-
muthdichloride revealed pyruvate dehydrogenase as
a target for this novel antibiotic (Birkenstock et al.
2012). A more detailed elucidation of the mechanism
of antibacterial action was demonstrated by isotope-
labelled metabolic ﬂux proﬁling of Escherichia coli
following antifolate exposure (Kwon et al. 2008).
Trimethoprim is a known inhibitor of dihydrofolate
reductase (DHFR), which was conﬁrmed by ac-
cumulation of oxidized folates in the treated cells.
However, an unexpected inhibiton of folylpoly-
gamma-glutamate-synthetase was also observed; a
response to dihydrofolate accumulation (Kwon et al.
2008). This systems-based approach allows obser-
vation of pharmacological eﬀects that often go un-
noticed in classical biochemical or genetic approaches
based on individual candidate drug targets. Here
we discuss the development of platforms that have
enabled measurement of hundreds of metabolites
in protozoa and their application to drug-target
identiﬁcation.
METABOLOMICS METHODOLOGY
Metabolomics studies fall into two broad categories,
targeted and untargeted. Targeted studies involve
hypothesis-driven experiments that aim to provide
accurate quantiﬁcation of a subset of known meta-
bolites, usually restricted to a particular metabolic
pathway or chemical class. Untargeted studies by
contrast are usually hypothesis-generating exper-
iments that provide relative quantiﬁcation of all
detectable metabolite signals, with subsequent iden-
tiﬁcation of the most signiﬁcant metabolites (Dunn
et al. 2012). Untargeted studies are particularly
attractive for the investigation of drugs of unknown
mode of action. Targeted studies inherently provide
less coverage of the metabolome, but have the advan-
tage of enabling accurate quantiﬁcation as well as ﬂux
analysis to determine dynamic responses in candidate
pathways (Kwon et al. 2008).
Sample preparation
Measurements of metabolic responses to drugs are
often obtained from in vitro cell culture systems
(Fig. 1). This approach allowsmaximum control over
genetic and environmental variables, such as temp-
erature, pH, atmosphere, extracellular environment
and cell density, which can contribute to unwanted
metabolic alterations and obscure the desired obser-
vation of drug-speciﬁc eﬀects (Cuperlovic-Culf et al.
2010). The choice of culture media may interfere
with drug action and/or metabolic responses, par-
ticularly when a standard culture medium does not
mimic the in vivo environment of the parasite. For
example, the high folate levels present in standard
Trypanosoma brucei culture medium, HMI11
(Hirumi and Hirumi, 1989), inhibits the in vitro
activity of antifolate compounds that demonstrate
trypanocidal activity in vivo (Sienkiewicz et al. 2008),
suggesting that culture media should be modiﬁed to
more closely reﬂect in vivo conditions wherever
possible. In addition, the impact of drug treatment
on parasite growth and viability can often alter
metabolite abundances, independent of the molecu-
lar target of the drug. Multiple controls, time courses
and drug concentrations are often necessary to de-
lineate mechanism-relatedmetabolic alterations from
non-speciﬁc stress responses (Vincent et al. 2012).
Intracellular parasites present unique challenges,
and isolation of parasites from uninfected host cells
should be performed to avoid interference from host
cell metabolites (e.g. saponin lysis or MACS puriﬁ-
cation for Plasmodium falciparum) (Zhang et al. 2011;
Biagini et al. 2012), although it is intriguing to
Fig. 1. General outline of methodology for metabolomics
studies of protozoan parasites in cell culture.
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consider how impacts on host cell metabolism can
contribute to the pharmacological eﬀect of a drug.
For example, human cytomegalovirus was shown to
lead to up-regulation of host cell fatty acid biosyn-
thesis and inhibitors of fatty acid biosynthesis could
inhibit viral growth (Munger et al. 2008). Meta-
bolomic analysis of uninfected host-cell response
to drug treatment is also recommended to conﬁrm
the parasite-speciﬁcity of drug-induced metabolic
changes. Care must be taken to avoid metabolic per-
turbation during any puriﬁcation step, and metabolic
quenching is often achieved by rapid cooling to 0 °C
(Saunders et al. 2011). Following quenching and
isolation of cells, metabolites are generally extracted
with organic solvent mixtures such as chloroform/
methanol/water (1:3:1) (Scheltema et al. 2010;
t’Kindt et al. 2010b).
Sample analysis
Metabolomics analysis is generally performed with
mass spectrometry or NMR spectroscopy. Mass
spectrometry is usually coupled to chromatographic
separation such as gas chromatography (GC-MS),
capillary electrophoresis (CE-MS) or liquid chrom-
atography (LC-MS) (Dunn et al. 2005; Scalbert et al.
2009; Scheltema et al. 2010; Creek et al. 2012a).
LC-MS with high resolution mass spectrometry is
becoming the most widely used metabolomics plat-
form due to its high sensitivity, broad speciﬁcity and
the ability to annotate or identify hundreds of polar
and non-polar metabolites from a wide range of
metabolic classes (Theodoridis et al. 2012). Reversed
phase chromatography is well established, and is
particularly suitable for analysis of lipids and other
non-polar metabolites (Theodoridis et al. 2012).
Hydrophilic interaction chromatography (HILIC)
is ﬁnding increasing application in metabolomics,
with particular advantages for the separation and
identiﬁcation of polar metabolites (Cubbon et al.
2009; Zhang et al. 2012). High resolution mass
spectrometry is critical for the detection and identiﬁ-
cation of metabolites in untargeted studies. Recent
advances in mass spectrometry have enabled wide-
spread application of untargeted metabolomics, as
most new time-of-ﬂight (TOF) and Fourier trans-
form (Orbitrap and FT-ICR) mass spectrometers
routinely achieve the required resolution (>30 000)
and mass accuracy (<5 ppm) (Dunn et al. 2012;
Theodoridis et al. 2012).
Data analysis
Computational approaches to metabolomics data
analysis are essential, as modern metabolomics plat-
forms routinely detect tens of thousands of ion
signals per sample. Many detected peaks arise from
noise, contaminants andLC-MS artefacts, and exten-
sive data processing is necessary to allow meaningful
interpretation of results (Jankevics et al. 2011; Kuhl
et al. 2011; Creek et al. 2012b; Weber et al. 2012).
Numerous open-source software packages are avail-
able to provide high-throughput detection, align-
ment, quantiﬁcation, ﬁltering and/or identiﬁcation
of metabolite signals, including XCMS, Metalign,
MZmine, mzMatch and IDEOM (Smith et al.
2006; Lommen, 2009; Pluskal et al. 2010; Scheltema
et al. 2011; Creek et al. 2012b). Pre-processed
metabolomics data provide relative metabolite abun-
dances for hundreds to thousands of putative
metabolites for interrogation by univariate or multi-
variate statistics (Liland, 2011; Vinaixa et al. 2012).
The major bottleneck for interpretation of un-
targeted metabolomics data is metabolite identiﬁ-
cation (Dunn et al. 2012). Many metabolites can be
putatively annotated by matching accurate masses
to the exact mass of metabolites in biochemical
databases. However, accurate metabolite identiﬁ-
cation is often hampered by metabolites with the
same (isomers) or similar (within the error margin of
the MS) mass (Scheltema et al. 2010). Conﬁrmation
of identiﬁcation requires orthogonal data such as frag-
mentation spectra (MS/MS) and chromatographic
retention time, and should be compared to authentic
standards (Sumner et al. 2007). Unfortunately, many
metabolite standards are not easily accessible, and
detectedmetabolites are often reported as putative, or
unknown, identities. Isolation and characterization
of unidentiﬁed metabolites is labour intensive, and is
generally only performed for a few metabolites that
show statistical signiﬁcance in a particular study.
Advanced biochemical interpretation of metabo-
lomics studies can be achieved by software solutions
that allow mapping of metabolite levels on to meta-
bolic pathways (Paley and Karp, 2006; Jourdan et al.
2010; Leader et al. 2011; Yamada et al. 2011). The
bottlenecks associated with metabolite identiﬁcation
limit the usefulness of these approaches, and path-
way-based analyses are best suited to targeted meta-
bolomics studies. A compromise approach, which
combines untargeted metabolomics with retention
time data from authentic standards to improve the
conﬁdence of putative metabolite identiﬁcations
(Creek et al. 2011), is supported by the IDEOM
software (Creek et al. 2012b). Interpretation of data in
the context of metabolic pathways may also improve
the accuracy ofmetabolite identiﬁcation (Rogers et al.
2009; Weber and Viant, 2010).
METABOLOMICS FOR INVESTIGATING THE
MODE OF ACTION OF ANTIPROTOZOAL DRUGS
Trypanocidal compounds
T. brucei is the causative agent of HAT, otherwise
known as sleeping sickness. Infection occurs follow-
ing the bite of a Tsetse ﬂy, and parasites remain in the
bloodstream during stage 1 disease, where symptoms
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are minor and non-speciﬁc (Barrett et al. 2007). Stage
2 disease occurs after parasites enter the central ner-
vous system, leading to neurological complications
including disturbed sleep-wake patterns. The infec-
tion is inevitably fatal if untreated. Five compounds
are approved for the treatment of HAT, but each has
serious limitations (Brun et al. 2011; Barrett and
Croft, 2012). Suramin and pentamidine must be
given by injection and are only eﬀective during stage
1 disease because they do not penetrate the blood-
brain barrier. Melarsoprol is active against both stage
1 and stage 2 disease, but this arsenical compound is
particularly toxic, with 5–10% of patients suﬀering
from reactive encephalopathy, which is often fatal.
Eﬂornithine alone, or in combination with nifurti-
mox is also active against stage 2 CNSdisease (Barrett
et al. 2007; Phillips, 2012). Clinical utilization of
eﬂornithine may be limited by the requirement for
administration of large doses by intravenous infu-
sion, and there is concern that resistance to these
drugs may develop rapidly (Vincent et al. 2010).
Eﬂornithine is the only compound among the ﬁve
approved drugs that has a well-deﬁned mode of
action, which involves inhibition of ornithine de-
carboxylase (ODC) and subsequent depletion of
polyamines (Grishin et al. 1999).
The mode of action of eﬂornithine was recently
conﬁrmed using untargetedmetabolomics, providing
a proof of concept that untargeted metabolomic
proﬁling of protozoan cell cultures is a powerful
tool for the unbiased determination of mode of action
for antiprotozoal compounds (Vincent et al. 2012).
Eﬂornithine induced signiﬁcant accumulation of
ornithine (the substrate for ODC), and depletion of
putrescine (the product of ODC), consistent with
direct inhibition of ODC by the drug (Fig. 2). The
only other metabolites to consistently show marked
changes in abundance were the acetylated forms
of ornithine and putrescine. This study also demon-
strated a signiﬁcant depletion of spermidine, the
downstreamproductof thepolyaminepathway.Inter-
estingly, only minor down-regulation was observed
for trypanothione, the spermidine-bis-glutathione
conjugate responsible for antioxidant activity in
trypanosomatids, suggesting that the trypanocidal
action of eﬂornithine is more likely related to
polyamine depletion than disruption of the anti-
oxidant defence system. Additional metabolite
changes were detected after 48 h incubation with
higher drug concentrations, highlighting the impor-
tance of metabolomic measurements across a dose-
range and time-course to delineate direct drug
mechanisms from downstream metabolic responses
that may include non-speciﬁc cell death pathways
(Vincent et al. 2012).
Metabolomic analysis of nifurtimox-treated cells
revealed a complex pattern of metabolic pertur-
bations, which could not be interpreted as inhibition
of a single metabolic enzyme (Vincent et al. 2012).
Altered abundances of nucleotide and glycolytic
metabolites were consistent with previous hypotheses
that implicate nucleic acid interactions and oxidative
stress as likely mediators of nifurtimox activity.
One advantage of the untargeted approach was the
detection of nifurtimox metabolites that support the
likely activationmechanism byT. brucei type-1 nitro-
reductase (Hall et al. 2011). In contrast to previous
hypotheses, nifurtimox was found to lack synergistic
activity with eﬂornithine, and metabolomics data
support this lack of synergism (Vincent et al. 2012).
The application of metabolomics to experimental
trypanocidal compounds can provide a method to
elucidate attractive drug targets for future drug dis-
covery. The impact of ﬂuorinated pyrimidines on
T. bruceimetabolismwas recently described (Ali et al.
2013). 5-ﬂuoro-2′-deoxyuridine resulted in speciﬁc
accumulation of dUMP in wild-type cells, and
minimal change in resistant cells, demonstrating
inhibition of thymidylate synthase, most likely by
the active metabolite, 5-ﬂuoro-dUMP. In contrast,
5-ﬂuorouracil and 5-ﬂuoroorotic acid were incorpor-
ated into the uracil nucleotide pool and then into
parasite RNA, revealing a distinct mode of action
for the ﬂuoropyrimidines compared to the ﬂuorode-
oxynucleoside (Ali et al. 2013). The metabolomics
platform has recently been applied to a variety of
currently used and experimental trypanocidal drugs
and work is following up on potential modes of action
identiﬁed in this way.
Antileishmania compounds
Leishmania spp. are trypanosomatid parasites re-
sponsible for a spectrum of diseases that include
visceral, cutaneous and mucocutaneous manifes-
tations of leishmaniasis. The infection is transmitted
by sand-ﬂy bite, and parasites develop mostly within
macrophages of the mammalian host (Naderer and
McConville, 2008). Treatment options for leishma-
niasis are severely limited, and the commonly used
treatments, pentavalent antimonials, amphotericin B,
miltefosine and paromomycin, have poor safety,
eﬃcacy and pharmacokinetic proﬁles (Barrett and
Croft, 2012). The mode of action of paromomycin
has been investigated by proteomics and, like other
aminoglycosides, appears to act by inhibition of
protein synthesis (Chawla et al. 2011). Amphotericin
B and miltefosine are thought to interact with sterols
and phospholipid metabolism, respectively (Lux
et al. 2000; Ouellette et al. 2004; Singh et al. 2012).
It is expected that metabolomic or lipidomic studies
would be able to conﬁrm the impact of these drugs
on lipid metabolism pathways to further characterize
the modes of action and resistance.
The mode of action of antimonial compounds is
a matter of debate, and is thought to be mediated
primarily by oxidative stress. A metabolomics
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approach using CE-MS demonstrated signiﬁcant
perturbation of sulphur-containing amino acids and
polyamine pathway metabolites following treatment
of Leishmania infantum promastigotes with Sb(III)
(Canuto et al. 2012). This ﬁnding is consistent with
depletion of trypanothione, the main metabolite re-
sponsible for redox homeostasis in trypanosomatids.
The mode of resistance to antimonials has also been
studied by metabolomics with LC-MS, which re-
vealed signiﬁcant alterations in the membrane lipid
composition of resistant L. donovani ﬁeld isolates
(t’Kindt et al. 2010a).
Antimalarial compounds
Plasmodium spp. are the infectious agents responsible
for malaria, with P. falciparum and P. vivax the
most common causative agents of human disease.
Plasmodium parasites undergo a complex life-cycle,
and are spread by the bite of an infectious mosquito,
with the symptomatic phase of disease occurring
during replication of asexual parasites within red
blood cells of the human host. Numerous drugs are
approved for treatment of malaria, although resist-
ance has emerged to most antimalarials (Dondorp
et al. 2009; White, 2012). Artemisinin combination
therapies (ACTs) are currently recommended due to
their potent activity and limited evidence of clinical
resistance to date (Anthony et al. 2012; Meshnick,
2012). Nevertheless, new antimalarials are urgently
required, as ACTs suﬀer from emerging resistance,
high cost and a pharmacokinetic mismatch between
short-acting artemisinins and long-acting partner
drugs, usually quinolines (Nosten and White, 2007;
Anthony et al. 2012). Artemisinins are thought to act
Fig. 2. Metabolomic response of Trypanosoma brucei to eﬂornithine over a 72 h incubation time-course (Vincent et al.
2012). (A) Heat map shows the relative change in abundance of all putative metabolites following incubation with
eﬂornithine. Putative metabolites are ranked according to fold-change at 72 h. The most signiﬁcant increases and
decreases correspond to metabolites of the polyamine pathway. (B) Metabolite abundance proﬁles of polyamine pathway
metabolites showing accumulation of metabolites upstream of ornithine decarboxylase (ODC), and depletion of
downstream metabolites. Y-axes represent peak heights from LC-MS data.
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by production of free radicals following exposure of
the peroxide pharmacophore to Fe(II) iron and/or
haem, which is released as a by-product of haemo-
globin digestion within the parasite (O’Neill et al.
2010). The quinoline antimalarials are also thought
to act by interaction with intraparasitic haem, and
preventing its detoxiﬁcation (Loria et al. 1999).How-
ever, the precise mode of action of most antimalarials
remains a matter of debate (Olliaro, 2001; O’Neill
et al. 2010). The antifolate antimalarials are known to
act by inhibition of DHFR and dihydropteroate
synthase (DHPS), but the clinical application of
these antifolates is limited by widespread resistance.
Nevertheless, characterization of the target enzyme,
DHFR, from wild-type and resistant parasites, has
lead to the design of novel antimalarial leads that
exhibit potent activity against the resistant enzyme
(Yuthavong et al. 2012). This demonstrates the
potential beneﬁt of understanding the targets of
current drugs as a paradigm for new drug discovery.
Atovaquone is another antimalarial with a known
mode of action, inhibition of the cytochrome bc1
complex in the mitochondrial electron transport
chain. This results in loss of the mitochondrial mem-
brane potential and subsequent disruption of pyr-
imidine synthesis by indirect inhibition of the
essential enzyme dihydroorotate dehydrogenase
(DHODH). The mode of action of atovaquone has
been conﬁrmed by a targeted metabolomics study
of P. falciparum, which demonstrated signiﬁcant
accumulation of dihydroorotate, the substrate of
DHODH, and its precursor, carbamoyl-L-aspartate
(Biagini et al. 2012). The mode of action for the novel
quinolone, CK-2-68, was also conﬁrmed by obser-
vation of the same metabolic response (Biagini et al.
2012).
Several compounds are currently under develop-
ment for the treatment of malaria, and metabolomics
studies may play an important role in deﬁning the
mode of action of new antimalarials. Fosmidomycin
is an antibiotic that acts on Plasmodium parasites
by inhibition of the essential non-mevalonate path-
way of isoprenoid biosynthesis. A targeted metabolic
proﬁling study of intermediates in the non-
mevalonate isoprenoid synthesis pathway conﬁrmed
deoxyxylulose phosphate reductoisomerase (DXR)
as the molecular target of the drug, and surprisingly,
identiﬁed a second target in the pathway, methyler-
ythritol phosphate cytidyltransferase (IspD) (Zhang
et al. 2011). The accumulation of all metabolites
upstream of IspD suggests that inhibition of this
enzyme, either directly by fosmidomycin or by
accumulation of 2-C-methylerythrose 4-phosphate,
is the primary mode of isoprenoid depletion in
P. falciparum (Zhang et al. 2011).
The response of P. falciparum in vitro cultures
to polyamine pathway inhibitors, eﬂornithine and
MDL73811, was investigated by targeted meta-
bolomics combined with transcriptomics and
proteomics. Polyamine depletion was conﬁrmed as
the primary mode of action, and unexpected
accumulation of glutamate metabolites could be
explained by transcriptional upregulation of or-
nithine aminotransferase in response to ornithine
accumulation (van Brummelen et al. 2009).
FUTURE DIRECTIONS
The suitability of metabolomics technology for
determination of the mode of action of antiprotozoal
compounds has been clearly demonstrated (Table 1).
Further developments in technology will be
necessary in order to expand the application of this
approach eﬃciently to all the currently available
antiprotozoal drugs, and the hundreds of compounds
that display antiprotozoal activity in vitro. Whilst
improvements in analytical hardware are expected to
continue to expand metabolite coverage and increase
sensitivity, the major issue limiting the accessibility
of high-throughput metabolomics is data analysis.
This situation is rapidly improving as evidenced by
many recent advances in freely available data analysis
software and web servers. However, it is expected
that automated identiﬁcation of metabolites will
remain a signiﬁcant bottleneck for untargeted meta-
bolomics for the foreseeable future (Dunn et al.
2012).
The ability to relate changes in metabolite abun-
dance to drug action remains largely dependent on a
priori knowledge of metabolic pathways within the
parasite. Unfortunately, many aspects of parasite
metabolism have not been fully elucidated, and often
rely on bioinformatic reconstructions of metabolic
pathways based on genomic homology with other
organisms. Many parasite genes are not annotated, or
annotated as hypothetical proteins, and it is likely
that some drugs will cause perturbations in meta-
bolites from uncharacterized pathways. In these
cases, untargeted metabolomics studies of drug
action are likely to provide signiﬁcant new discoveries
in basic parasite biochemistry, as has already been
demonstrated for polyamine acetylation (Vincent
et al. 2012) and pyrimidine metabolism (Ali et al.
2013) in T. brucei, and the two-step DXR reaction in
P. falciparum isoprenoid biosynthesis (Zhang et al.
2011).
The major advantage of untargeted metabolomics
is the ability to identify a drug-mediated response at
the biochemical level with no prior knowledge of the
mode of action of a particular antiprotozoal com-
pound. This method can be used to classify com-
pounds according to their mode of action based on a
metabolic signature and, in many cases, highlight the
speciﬁc metabolic enzyme or pathway responsible for
antiprotozoal activity. The primary limitation of this
approach is that some drugs do not act by disruption
of metabolic pathways. In addition, drugs may
induce non-speciﬁc metabolic changes in response
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to stress, or as secondary responses to the initial drug
action. Targeted metabolomics approaches are often
required in these circumstances to provide a detailed
characterization of the temporal and dose-dependent
biochemical eﬀects of drugs. Additional studies, such
as transcriptomics, may also be required to delineate
primary and secondary metabolic responses to drug
treatment (van Brummelen et al. 2009). Generally,
measurements of RNA or protein levels are unlikely
to reveal the primary targets of drugs that inhibit
metabolic enzymes, particularly in trypanosomatid
parasites that exhibit polycistronic transcription.
Nevertheless, transcriptomic and proteomic ap-
proaches are likely to detect the secondary cellular
responses to drug treatment, which may be relevant
to determination of potential resistance mechanisms.
A systems biology approach, that combines meta-
bolomics with other functional genomics tools, is
a promising avenue to obtain comprehensive de-
scriptions of the modes of action and resistance for
antimicrobial drugs. Metabolomics may also be
combined with chemical biology (e.g. protein or
ligand microarrays (MacBeath et al. 1999) and
chemoinformatic methods (e.g. similarity ensemble
approach - Keiser et al. 2010) to improve identiﬁ-
cation of unknown drug targets in an untargeted
manner.
Metabolomics methods oﬀer eﬀective tools for
the identiﬁcation and characterization of mech-
anisms of drug action, which should optimize drug
discovery by allowing detailed pre-clinical pharmaco-
kinetic/pharmocodynamic descriptions of antiproto-
zoal drugs, and have the potential to translate into
clinical studies to monitor both host and parasite
responses to drug treatment (Beyoğlu and Idle,
2013).
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Table 1. Examples of applications of metabolomics to determine the mode of action of drugs and other
compounds with antimicrobial activity
Organism Test compound
Metabolomics
approach Target identiﬁed Reference
T. brucei Eﬂornithine Untargeted LC-MS
(HILIC-Orbitrap)
Ornithine decarboxylase (Vincent et al.
2012)
T. brucei Nifurtimox Untargeted LC-MS
(HILIC-Orbitrap)
Complex: involves
nucleotides, oxidative stress
and an active metabolite
(Vincent et al.
2012)
T. brucei 5-ﬂuoro-2′-deoxyuridine Untargeted LC-MS
(HILIC-Orbitrap)
Thymidylate synthase
inhibited
by active metabolite
(Ali et al. 2013)
T. brucei 5-ﬂuoroorotate and
5-ﬂuorouracil
Untargeted LC-MS
(HILIC-Orbitrap)
RNA modiﬁcation
(ﬂuorinated uracil residues)
(Ali et al. 2013)
L. infantum Antimony (III) Untargeted CE-MS
(CE-TOF)
Oxidative stress (sulphur
amino acids and polyamines)
(Canuto et al.
2012)
P. falciparum Atovaquone and CK-2-68 Targeted LC-MS
(HILIC-QQQ)
Dihydroorotate
dehydrogenase (via
mitochondrial electron
transport chain)
(Biagini et al.
2012)
P. falciparum Fosmidomycin Targeted LC-MS
(ion paired reversed-
phase – QQQ)
Methylerythritol
phosphate cytidyltransferase
(IspD) and deoxyxylulose
phosphate
reductoisomerase (DXR)
(Zhang et al. 2011)
P. falciparum Eﬂornithine with
MDL73811
Targeted LC-MS
(HILIC-QQQ)
Polyamine synthesis (van Brummelen
et al. 2009)
Staphylococcus
aureus
Triphenylbismuth
dichloride
Targeted 1H NMR Pyruvate dehydrogenase (Birkenstock et al.
2012)
S. aureus Guanidinomethylbenzoates
and guanidinobenzamides
Untargeted GC-MS Classiﬁed as having similar
mechanism to clindamycin
(Liu et al. 2009)
Escherichia coli Trimethoprim Targeted LC-MS
(HILIC-QQQ)
Dihydrofolate reducatase
and folylpoly-γ-glutamate
synthetase
(Kwon et al. 2008)
E. coli
Pseudomonas
aeruginosa
11 common antibiotics Targeted CE-UV Classiﬁcation of mechanisms
by correlation analysis
(Gao et al. 2007)
Mycobacterium
smegmatis
12 drugs and 3
chemical leads
Untargeted 1H NMR Classiﬁcation of mechanisms
by multivariate analysis
(Halouska et al.
2012)
M. smegmatis D-cycloserine Untargeted 1H NMR D-alanine-D-alanine ligase (Halouska et al.
2007)
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